摘要
背景:磷酸二酯酶5抑制剂(PDE5)sildenafil, vardenafil, tadalafil和最近批准的avanafil是勃起功能障碍慢性治疗和按需治疗的首选。除此之外,sildenafil和 tadalafil也被批准用于治疗肺动脉高血压。由于在许多组织中的表达和定位,PDE5酶及其调控已被报道与多种疾病有关。目的:对PDE5新的治疗应用进行概述,并讨论其最新的研究报告。方法:在在线数据库(PubMed,Reaxys,Scopus)的基础上,我们的注意力集中在最近的研究报告,特别是有关临床前和临床数据的报告。结果:PDE5调控可能影响病理条件等,其中包括心脏衰竭、囊性纤维化、肿瘤、中枢神经系统相关的疾病、糖尿病和影响男性泌尿和生殖系统功能障碍的疾病。结论:Sildenafil, vardenafil, tadalafil和其他的PDE5-Is药物呈现出阳性结果,并在研究的疾病中有显著的提高,因此,必须指出一些阴性结果,特别是与临床前和临床数据进行比较时。这意味着对PDE5-Is药物需要进一步的研究,特别是评估其确切的分子途径。
关键词: PDE5,sildenafil,抗癌,多目标,囊性纤维化,勃起功能障碍。
Current Medicinal Chemistry
Title:New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Volume: 23 Issue: 12
Author(s): Giovanni Ribaudo, Mario Angelo Pagano, Sergio Bova, Giuseppe Zagotto
Affiliation:
关键词: PDE5,sildenafil,抗癌,多目标,囊性纤维化,勃起功能障碍。
摘要: Background: Phosphodiesterase 5 inhibitors (PDE5-Is) sildenafil, vardenafil, tadalafil and the recently approved avanafil represent the first-line choice for both on-demand and chronic treatment of erectile dysfunction (ED). In addition to this, sildenafil and tadalafil, have also been approved for the treatment of pulmonary arterial hypertension. Due to its expression and localization in many tissues, PDE5 and its regulation has been reported to be involved in several other diseases. Objective: We aim to provide an updated overview of the emerging therapeutic applications of PDE5-Is besides ED, taking into account the latest ongoing research reports. Methods: We searched online databases (Pubmed, Reaxys, Scopus) to lay the bases for an accurate, quality criteria-based literature update. We focused our attention on most recent research reports, in particular when supported by pre-clinical and clinical data. Results: The regulation of PDE5 may influence pathological conditions such as, among the others, heart failure, cystic fibrosis, cancer, CNS-related diseases, diabetes and dysfunctions affecting male urinary/reproductive system. Conclusion: Sildenafil, vardenafil, tadalafil and the other chemical entities considered PDE5-Is showed overall positive results and significant improvements in the studied disease, thus some discordant results, in particular when comparing pre-clinical and clinical data, have to be pointed out, suggesting that further insights are needed especially to assess the exact molecular pathway underlying.
Export Options
About this article
Cite this article as:
Giovanni Ribaudo, Mario Angelo Pagano, Sergio Bova, Giuseppe Zagotto , New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is), Current Medicinal Chemistry 2016; 23 (12) . https://dx.doi.org/10.2174/0929867323666160428110059
DOI https://dx.doi.org/10.2174/0929867323666160428110059 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine Malignant Mesothelioma: Biology, Diagnosis and Therapeutic Approaches
Current Molecular Pharmacology Insights Into the Role of microRNAs in Cardiac Diseases: From Biological Signalling to Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Bile Acids and Farnesoid X Receptor: Novel Target for the Treatment of Diabetic Cardiomyopathy
Current Protein & Peptide Science Current Landscape of Natural Products against Coronaviruses: Perspectives in COVID-19 Treatment and Anti-viral Mechanism
Current Pharmaceutical Design An Increasing Incidence of Treatment Resistance in Hypertension?
Current Drug Therapy Tramadol Induced QTc-Interval Prolongation: Prevalence, Clinical Factors and Correlation to Plasma Concentrations
Current Drug Safety Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment
Current Cancer Drug Targets Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design Pharmacological Activity of Natural Non-glycosylated Triterpenes
Mini-Reviews in Organic Chemistry Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Current Vascular Pharmacology Tetrahydrobiopterin Biosynthesis, Utilization and Pharmacological Effects
Current Drug Metabolism Smoking and Cardiovascular System: Cellular Features of the Damage
Current Pharmaceutical Design Sirolimus Eluting Stent: A New Era in Interventional Cardiology?
Current Pharmaceutical Design ATP-Sensitive Potassium Channels
Current Pharmaceutical Design The Retinal Pigment Epithelium in Health and Disease
Current Molecular Medicine Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients
Current Vascular Pharmacology